



DIAGNOS
Your Knowledge Partner

OTCQB: DGNOF
TSXV: ADK
SOURCE: DIAGNOS Inc.

PRESS RELEASE

2023.05.17

DIAGNOS and IRIS, The Visual Group strengthen partnership with the launch of “IRIS-ai powered by DIAGNOS”

I R I S - a i
powered by DIAGNOS

BROSSARD, Quebec, Canada – May 17, 2023 - DIAGNOS Inc. (“**DIAGNOS**”, the “**Corporation**” or “we”) (TSX Venture: ADK) (OTCQB: DGNOF) a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (**AI**), is pleased to announce the launch of “IRIS-ai powered by DIAGNOS” by IRIS, The Visual Group, in partnership with DIAGNOS.

For over two years, IRIS and DIAGNOS have joined forces to advance and combine technological innovations and provide front-line clinical experience to improve patient care through early detection and follow-up of various ocular diseases, with the training of DIAGNOS algorithms and with the help of annotations from 30 IRIS optometrists. A total of 14,000 patients across Quebec were screened, generating a comprehensive databank with images of patients across the province, reflecting the diversity of patients in Quebec.

"At IRIS, we believe that delivering the best optometric service to our patients is achieved through an unwavering commitment to innovation and research. We are proud to not only invest significant financial resources but also in our investment in human expertise, to remain at the forefront of our field, and to continue to offer top quality optometric care", states **Éric Babin, President of IRIS**.

Under the Quebec Ministry of Economy, Innovation and Energy's INVEST-AI initiative, a pilot program was submitted by the two partners in 2020, followed by a subsidy to adapt the AI technology in a commercial context one year later. Participating IRIS optometrists contributed their clinical expertise by validating the analyses of the algorithms, ensuring their relevance and accuracy.

"For us, it was essential to partner with a company that not only attaches importance to a rigorous and precise scientific framework, but that proposes a tool designed to guarantee ethical and transparent standards at every level while providing an added layer of support to optometrists throughout the province," adds **André Larente, President of DIAGNOS**.

IRIS-ai is currently being deployed in all of Quebec and will be gradually introduced to all 150 stores in the rest of Canada.

About DIAGNOS

DIAGNOS is a publicly traded Canadian corporation dedicated to early detection of critical health problems based on its FLAIRE Artificial Intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications such as CARA (Computer Assisted Retina Analysis). CARA's image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients. CARA has been cleared for commercialization by the following regulators: Health Canada, the FDA (USA), CE (Europe), COFEPRIS (Mexico) and Saudi FDA (Saudi Arabia).

Additional information is available at www.diagnos.com and www.sedar.com

About IRIS

IRIS was founded in 1990 in Quebec. Over the years, IRIS has evolved into the largest network of optometrists, opticians, and ophthalmologists operating under the same banner across Canada. The company's locations combine clinical optometry and optical retail to provide a unique concept and a commitment to offering superior eye care products and services.

Additional information is available at www.iris.ca or on their LinkedIn page.

For further information about this Press Release, please contact:

Mr. André Larente, President
DIAGNOS Inc.
Tel: 450 678-8882, ext. 224
Email: alarente@diagnos.com

Jennifer Ahken
EGS PR, responsible of Media Inquiries for IRIS, The Visual Group
Tel: 514-952-2072
Email: ja@egspr.com

This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.